News
What Happened in the Stock Market Today
Stocks finished the week on a positive note Friday, with the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) in positive territory throughout the session and....
What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's predominantly grown through acquisitions and drug-price increases over the years, surged as much as 11% by 3 p.m. EST....
Here's Why Radius Health Is Rising Today
After presenting data from a phase 1 study at a medical conference, shares of Radius Health (NASDAQ: RDUS), a commercial-stage biotech focused on osteoporosis and cancer, rose 15% as of 11:15 a.m.....
A Game-Changing Breakthrough Could Be Coming for Hemophilia Patients
Patients diagnosed with hemophilia B suffer a lifetime of treatment, but that could change based on recently reported data from an early stage trial Pfizer (NYSE: PFE) and Spark Therapeutics....
Immunomedics' Data Is Good News for Seattle Genetics, Too
Seattle Genetics' (NASDAQ: SGEN) deal to license Immunomedics' (NASDAQ: IMMU) sacituzumab govitecan, a breast cancer drug, was shelved earlier this year when activist investor venBio Select....
Why Sage Therapeutics Gained 70% Today
Shares of Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biotech, took flight today, after the company announced positive mid-stage trial results for its moderate-to-severe major depressive....
What Happened in the Stock Market Today
Stocks moved higher on Thursday, with the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) both up a little more than a quarter percentage point.Data source:....
Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday
Shares of clinical-stage biopharma Marinus Pharmaceuticals (NASDAQ: MRNS) rose over 41% today after larger peer Sage Therapeutics (NASDAQ: SAGE) reported positive top-line results for one of its....
Is Exelixis, Inc. a Buy?
Yes.I know I'm breaking all the rules about building up suspense, etc. But I think Exelixis (NASDAQ: EXEL) is a buy right now. I think the stock will go higher over the next few years. Don't just....
Is Exact Sciences Corporation (EXAS) a Buy?
Some investors look at a stock that has nearly quadrupled in price within less than 12 months and are excited about buying it. Others look at the same stock and are afraid that the momentum could....
Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In November
A month full of news related to the progress it's making toward helping patients with Duchenne muscular dystrophy (DMD) sparked a 12.9% rally in Sarepta Therapeutics (NASDAQ: SRPT) shares last....
Here's What Caused This Marijuana Stock to Skyrocket 15% in November
Medical marijuana has been used to treat epilepsy in patients for years, but so far, it's efficacy and safety hasn't been supported by a regulatory green light from the Food and Drug....
Here's Why bluebird bio's Shares Soared 24% in November
After bluebird bio (NASDAQ: BLUE) updated investors on the presentations it will be making at a key industry conference soon, its shares jumped 24.2% in November, according to S&P Global....
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Better luck next year. That's what Merck & Co. (NYSE: MRK) is hoping for after a disappointing 2017. Merck stock is down year to date by 7%, while the S&P 500 index is up close to 18%.Will....
2 Top Consumer Staples Stocks to Consider Buying Now -- and 1 to Avoid
Recessions are common enough that you can count on several of them impacting your portfolio over the course of even a 10-year time horizon. That's just one reason why consumer staples stocks --....
Why Immunomedics, Inc. Is Soaring Today
After Immunomedics (NASDAQ: IMMU) shared some positive clinical data with investors, shares of the clinical-stage biotech focused on cancer rose 17% as of 3:10 p.m. EST on Wednesday.Immunomedics....
Why Madrigal Pharmaceuticals Stock Is On Fire Today
Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) are rocketing higher today after the company announced positive mid-stage results for its experimental non-alcoholic steatohepatitis (NASH)....
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biopharmaceutical company that develops treatments for eye disorders and other serious medical conditions, tumbled 10% during the....
ALPHA MOS : Informations relatives au nombre total de droits de vote
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Why Alnylam Pharmaceuticals Rose 12.7% in November
In response to the company sharing a slew of positive developments with investors, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a clinical-stage biotech focused on RNAi therapies, jumped 13%....
Depomed Executes an Exit Strategy for Its Opioid Drug
After reporting that Collegium Pharmaceutical (NASDAQ: COLL) will take over commercializing its top-selling drug, Nucynta, Depomed Inc. (NASDAQ: DEPO) shares rallied 10% yesterday. The pact is....
Here's Why Editas Medicine Inc. Stock Is Slipping Today
Shares of Editas Medicine Inc. (NASDAQ: EDIT), a biotech that aims to correct disease‑causing genes with CRISPR technology, are in retreat following the pricing of a secondary share offering this....
The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November
Shares of Novavax (NASDAQ: NVAX), a clinical-stage small-cap biotech company focused on the development of recombinant nanoparticle vaccines, surged by 25% during the month of November, according....
2 Reasons Geron Corporation Took a Pounding in November
Shares of Geron Corporation (NASDAQ: GERN), a clinical-stage biotech company focused on the development of oncology drugs, sank 12% during the month of November, according to data from S&P....
The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drugmaker that had primarily grown by acquisitions and drug-price hikes in recent years, galloped higher by 43% in November, according....